Search by category - Any -Regulated informationInside informationNon-regulated information Search by year - Any -2024202320222021202020192018201720162015 31 October 2022 Biocartis Announces Nine Idylla™ Studies to be Published at Upcoming AMP 2022 Annual Meeting Non-regulated information 10 October 2022 Biocartis Initiates Commercialization in Europe of HepatoPredict (CE-IVD) Test for Liver Cancer Patients Non-regulated information 1 September 2022 Biocartis Initiates Commercialization in Europe of SkylineDx’s Innovative Merlin™ Assay (CE-IVD) for Melanoma Patients Non-regulated information 24 August 2022 Biocartis Obtains ISO 27001 Certification for Information Security Management Non-regulated information 22 June 2022 Biocartis Announces New Agreement with AstraZeneca for the Development and Marketing of a Companion Diagnostic Test for Tagrisso® Non-regulated information 20 June 2022 Biocartis Announces Launch of its Rapid CE-marked IVD Idylla™ GeneFusion Panel for Fast Treatment Decisions in Lung Cancer Non-regulated information 15 June 2022 Biocartis Reaches Key Commercial Milestones: One-Millionth Idylla™ Cartridge Sold and 2,000th Idylla™ Instrument Placed Non-regulated information 4 May 2022 New Study Led by Memorial Sloan Kettering Cancer Center (NY, US) Shows Idylla™ GeneFusion Assay Enables More Rapid Screening of Targetable Fusions Compared to Routine Methods Non-regulated information 25 April 2022 Biocartis Announces Presentation of Three Idylla™ Studies at 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Non-regulated information 21 April 2022 Biocartis Announces Presentation of First Prospective Validation Study Data of Merlin Test by Partner SkylineDx at EADO 2022 Conference Non-regulated information Pagination First page « First Previous page ‹‹ Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page ›› Last page Last »